Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04071223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 303 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Final enrollment: 98 participants (planned 134) Primary completion date changed from estimate of Oct 1, 2026 to Jul 27, 2026 · Completion pushed from Oct 1, 2026 to Sep 24, 2027 · Site details revised at 8 of 47 sites Show 3 more changesShow less
    • Primary completion date changed from estimate of Oct 1, 2026 to Jul 27, 2026
    • Completion pushed from Oct 1, 2026 to Sep 24, 2027
    • Site details revised at 8 of 47 sites
  2. Study Status, Contacts/Locationsv302
  3. 48 versions Re-verified since Feb 4, 2026, no change to tracked fieldsv254-v301
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Trial Details
NCT Number NCT04071223
Lead Sponsor National Cancer Institute (NCI)
Conditions Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 +1 more
Enrollment 98 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov